CCIA
RCUS icon

Campbell & Co Investment Adviser’s Arcus Biosciences RCUS Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-165,474
Closed -$1.3M – 1414
2025
Q1 		$1.3M Buy
+165,474
New +$1.92M 0.1% 326
2024
Q2 		– Sell
-37,496
Closed -$708K – 1294
2024
Q1 		$708K Sell
37,496
-25,398
-40% -$439K 0.06% 542
2023
Q4 		$1.2M Buy
+62,894
New +$1.01M 0.11% 307

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Campbell & Co Investment Adviser's RCUS Position: Q2 2025 in Review

Campbell & Co Investment Adviser sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 165,474 shares — an estimated $1.3M sold.

Campbell & Co Investment Adviser first reported a position in RCUS in Q4 2023 and held it in 3 quarters. The position peaked at $1.3M in Q1 2025. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

  • Campbell & Co Investment Adviser reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 165,474 Arcus Biosciences shares in Q2 2025, an estimated $1.3M.
  • Campbell & Co Investment Adviser first reported a position in Arcus Biosciences in Q4 2023 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Arcus Biosciences position peaked at $1.3M in Q1 2025.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2025, filed 7 Aug 2025.